Belgium-based IBA (Ion Beam Applications) is hawking its two-room proton therapy solution this week at the American Society for Therapeutic Radiology and Oncology (ASTRO) meeting as a smaller, lower-cost alternative to traditional proton therapy centers.
Belgium-based IBA (Ion Beam Applications) is hawking its two-room proton therapy solution this week at the American Society for Therapeutic Radiology and Oncology (ASTRO) meeting as a smaller, lower-cost alternative to traditional proton therapy centers. The IBA configuration, dubbed Proteus Nano, starkly contrasts the often two-story proton therapy centers that occupy as much as 100,000 square feet. The company is framing Proteus Nano as requiring a much smaller footprint and imposing a lower acquisition cost, while still providing the highly accelerated proton beams needed to kill cancer tumors.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.
Emerging MRI Scoring System May Help Predict Recurrent and Metastatic Hepatocellular Carcinoma
February 12th 2025Preoperative use of the scoring system for gadoxetic acid-enhanced MRI demonstrated an average AUC of 85 percent and average specificity of 89 percent in external validation cohorts for pathologic features of hepatocellular carcinoma.
Key Chest CT Parameters for Body Composition May be Prognostic for Patients with Resectable NSCLC
February 11th 2025A high intermuscular adipose index has a 49 percent increased likelihood of being associated with lower overall survival in patients with resectable non-small cell lung cancer (NSCLC), according to new research.